{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:17:50Z","timestamp":1790399870312,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.lfs.2022.121105","type":"journal-article","created":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T11:12:18Z","timestamp":1666177938000},"page":"121105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"PA","title":["Anti-tumor effects and mechanism of a novel camptothecin derivative YCJ100"],"prefix":"10.1016","volume":"311","author":[{"given":"Mi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Zu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Fei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Zeng","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Yin","family":"Kai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Qian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan-Rui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2022.121105_bb0005","series-title":"Camptothecin and Taxol: Historic Achievements in Natural Products Reseach","author":"Oberlies","year":"2004"},{"key":"10.1016\/j.lfs.2022.121105_bb0010","series-title":"Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor From Camptotheca acuminata","author":"Soc","year":"1966"},{"issue":"4","key":"10.1016\/j.lfs.2022.121105_bb0015","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/(SICI)1098-1128(199707)17:4<367::AID-MED3>3.0.CO;2-U","article-title":"Recent advances in the discovery and development of topoisomerase inhibitors as antitumor agents","volume":"17","author":"Wang","year":"1997","journal-title":"Med. Res. Rev."},{"issue":"3","key":"10.1016\/j.lfs.2022.121105_bb0020","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.1998.16.3.945","article-title":"Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a pediatric oncology group study","volume":"16","author":"Saylors","year":"1998","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.lfs.2022.121105_bb0025","first-page":"331","article-title":"Effectiveness of water soluble poly(L-glutamic acid)-camptothecin conjugate against resistant human lung cancer xenografted in nude mice","volume":"18","author":"Zou","year":"2001","journal-title":"Int. J. Oncol."},{"issue":"12","key":"10.1016\/j.lfs.2022.121105_bb0030","first-page":"3248","article-title":"Increased expression of DNA topoisomerase I gene and collateral sensitivity to camptothecin in human cisplatin-resistant bladder cancer cells","volume":"54","author":"Kotoh","year":"1994","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.lfs.2022.121105_bb0035","doi-asserted-by":"crossref","first-page":"370","DOI":"10.2174\/1574892814666191016162346","article-title":"Mechanism of a novel camptothecin-deoxycholic acid derivate induced apoptosis against human liver cancer HepG2 cells and human colon cancer HCT116 cells","volume":"14","author":"Xiao","year":"2019","journal-title":"Recent Pat. Anticancer Drug Discov."},{"key":"10.1016\/j.lfs.2022.121105_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110309","article-title":"The novel camptothecin derivative, CPT211, induces cell cycle arrest and apoptosis in models of human breast cancer","volume":"128","author":"Chiu","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.lfs.2022.121105_bb0045","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1471-2407-4-32","article-title":"Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma","volume":"4","author":"Bathe","year":"2004","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.lfs.2022.121105_bb0050","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1097\/JTO.0b013e318260de75","article-title":"Topotecan\/cisplatin compared with cisplatin\/etoposide as first-line treatment for patients with extensive disease small-cell lung cancer final results of a randomized phase III trial","volume":"7","author":"Fink","year":"2012","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.lfs.2022.121105_bb0055","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00280-010-1510-y","article-title":"Phase 1\/pharmacology study of intraperitoneal topotecan alone and with cisplatin: potential for consolidation in ovarian cancer","volume":"68","author":"Andreopoulou","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"11","key":"10.1016\/j.lfs.2022.121105_bb0060","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S0145-2126(99)00133-2","article-title":"Pre-clinical evaluation of SN-38 and novel camptothecin analogs against human chronic B-cell lymphocytic leukemia lymphocytes","volume":"23","author":"Cohen","year":"1999","journal-title":"Leuk. Res."},{"issue":"7","key":"10.1016\/j.lfs.2022.121105_bb0065","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.jvir.2015.03.020","article-title":"Transarterial hepatic chemoembolization with 70\u2013150 microm drug-eluting beads: assessment of clinical safety and liver toxicity profile","volume":"26","author":"Odisio","year":"2015","journal-title":"J. Vasc. Interv. Radiol."},{"issue":"1","key":"10.1016\/j.lfs.2022.121105_bb0070","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1124\/mol.52.1.82","article-title":"Novel 7-alkyl methylenedioxy-camptothecin derivatives exhibit increased cytotoxicity and induce persistent cleavable complexes both with purified mammalian topoisomerase I and in human colon carcinoma SW620 cells","volume":"52","author":"Valenti","year":"1997","journal-title":"Mol. Pharmacol."},{"issue":"4","key":"10.1016\/j.lfs.2022.121105_bb0075","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s002800000157","article-title":"Camptothecin analogues with enhanced antitumor activity at acidic pH","volume":"46","author":"Adams","year":"2000","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"20","key":"10.1016\/j.lfs.2022.121105_bb0080","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1021\/bi00071a010","article-title":"Lipid bilayer partitioning and stability of camptothecin drugs","volume":"32","author":"Burke","year":"1993","journal-title":"Biochemistry"},{"issue":"1","key":"10.1016\/j.lfs.2022.121105_bb0085","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1021\/cr0780210","article-title":"Camptothecins: a SAR\/QSAR study","volume":"109","author":"Verma","year":"2009","journal-title":"Chem. Rev."},{"issue":"6","key":"10.1016\/j.lfs.2022.121105_bb0090","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.bcp.2007.10.016","article-title":"Next generation topoisomerase I inhibitors: rationale and biomarker strategies","volume":"75","author":"Teicher","year":"2008","journal-title":"Biochem. Pharmacol."},{"issue":"3","key":"10.1016\/j.lfs.2022.121105_bb0095","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1021\/acs.jmedchem.7b01297","article-title":"Neutral porphyrin derivative exerts anticancer activity by targeting cellular topoisomerase I (Top1) and promotes apoptotic cell death without stabilizing Top1-DNA cleavage complexes","volume":"61","author":"Das","year":"2018","journal-title":"J. Med. Chem."},{"issue":"17","key":"10.1016\/j.lfs.2022.121105_bb0100","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.2174\/092986706777585004","article-title":"Review camptothecin: current perspectives","volume":"13","author":"Li","year":"2006","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.lfs.2022.121105_bb0105","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejmech.2016.09.019","article-title":"Novel 2-aryl-4-(4'-hydroxyphenyl)-5H-indeno[1,2-b]pyridines as potent DNA non-intercalative topoisomerase catalytic inhibitors","volume":"125","author":"Park","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.lfs.2022.121105_bb0110","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1039\/B711844A","article-title":"Understanding organofluorine chemistry. An introduction to the C-F bond","volume":"37","author":"O'Hagan","year":"2008","journal-title":"Chem. Soc. Rev."},{"issue":"17","key":"10.1016\/j.lfs.2022.121105_bb0115","doi-asserted-by":"crossref","first-page":"9073","DOI":"10.1021\/cr500706a","article-title":"Monofluorination of organic compounds: 10 years of innovation","volume":"115","author":"Champagne","year":"2015","journal-title":"Chem. Rev."},{"issue":"21","key":"10.1016\/j.lfs.2022.121105_bb0120","doi-asserted-by":"crossref","first-page":"8315","DOI":"10.1021\/acs.jmedchem.5b00258","article-title":"Applications of fluorine in medicinal chemistry","volume":"58","author":"Gillis","year":"2015","journal-title":"J. Med. Chem."},{"issue":"14","key":"10.1016\/j.lfs.2022.121105_bb0125","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.2174\/156802606777951109","article-title":"Fluorinated natural products with clinical significance","volume":"6","author":"Thomas","year":"2006","journal-title":"Curr. Top. Med. Chem."},{"issue":"24","key":"10.1016\/j.lfs.2022.121105_bb0130","first-page":"6330","article-title":"Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients","volume":"54","author":"Rivory","year":"1994","journal-title":"Cancer Res."},{"issue":"24","key":"10.1016\/j.lfs.2022.121105_bb0135","doi-asserted-by":"crossref","first-page":"15387","DOI":"10.1073\/pnas.242259599","article-title":"The mechanism of topoisomerase I poisoning by a camptothecin analog","volume":"99","author":"Staker","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lfs.2022.121105_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111971","article-title":"Design, synthesis and antineoplastic activity of novel 20(S)-acylthiourea derivatives of camptothecin","volume":"187","author":"Yang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.lfs.2022.121105_bb0145","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.bmcl.2016.12.085","article-title":"The long story of camptothecin: from traditional medicine to drugs","volume":"27","author":"Martino","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.lfs.2022.121105_bb0150","series-title":"Molecular Imaging and Contrast Agent Database (MICAD)","article-title":"Avidin conjugated to tetramethyl-6-carboxyrhodamine-QSY((R))7","author":"Chopra","year":"2004"},{"issue":"6","key":"10.1016\/j.lfs.2022.121105_bb0155","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1007\/s005340070002","article-title":"Precancerous lesions of intrahepatic cholangiocarcinoma","volume":"7","author":"Shimonishi","year":"2000","journal-title":"J. Hepato-Biliary-Pancreat. Surg."},{"issue":"2","key":"10.1016\/j.lfs.2022.121105_bb0160","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/jps.2600630203","article-title":"Camptothecin","volume":"63","author":"Shamma","year":"1974","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.lfs.2022.121105_bb0165","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.biopha.2016.06.008","article-title":"Directional modification of chrysin for exerting apoptosis and enhancing significantly anti-cancer effects of 10-hydroxy camptothecin","volume":"82","author":"Tang","year":"2016","journal-title":"Biomed. Pharmacother."},{"issue":"9","key":"10.1016\/j.lfs.2022.121105_bb0170","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1634\/theoncologist.10-9-686","article-title":"Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis","volume":"10","author":"Armstrong","year":"2005","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.lfs.2022.121105_bb0175","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/med.21342","article-title":"Perspectives on biologically active camptothecin derivatives","volume":"35","author":"Liu","year":"2015","journal-title":"Med. Res. Rev."},{"issue":"40","key":"10.1016\/j.lfs.2022.121105_bb0180","doi-asserted-by":"crossref","first-page":"25796","DOI":"10.18632\/oncotarget.25376","article-title":"Camptothecin exhibits topoisomerase1-independent KMT1A suppression and myogenic differentiation in alveolar rhabdomyosarcoma cells","volume":"9","author":"Wolff","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.lfs.2022.121105_bb0185","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.ejps.2018.08.018","article-title":"Two novel camptothecin derivatives inhibit colorectal cancer proliferation via induction of cell cycle arrest and apoptosis in vitro and in vivo","volume":"123","author":"Du","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.lfs.2022.121105_bb0190","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0090-9556(24)15060-X","article-title":"Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients","volume":"28","author":"Slatter","year":"2000","journal-title":"Drug Metab. Dispos."},{"issue":"8","key":"10.1016\/j.lfs.2022.121105_bb0195","first-page":"2182","article-title":"Clinical pharmacokinetics and metabolism of irinotecan (CPT-11)","volume":"7","author":"Mathijssen","year":"2001","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.lfs.2022.121105_bb0200","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1021\/bc0155420","article-title":"Identification and activities of human carboxylesterases for the activation of CPT-11, a clinically approved anticancer drug","volume":"12","author":"Senter","year":"2001","journal-title":"Bioconjug. Chem."},{"issue":"1","key":"10.1016\/j.lfs.2022.121105_bb0205","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/bmc.1345","article-title":"Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives","volume":"24","author":"Ramesh","year":"2010","journal-title":"Biomed. Chromatogr."},{"issue":"1\u20132","key":"10.1016\/j.lfs.2022.121105_bb0210","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ijpharm.2016.10.058","article-title":"The use of surfactants to enhance the solubility and stability of the water-insoluble anticancer drug SN38 into liquid crystalline phase nanoparticles","volume":"515","author":"Ranneh","year":"2016","journal-title":"Int. J. Pharm."},{"issue":"12","key":"10.1016\/j.lfs.2022.121105_bb0215","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1093\/annonc\/mdf337","article-title":"Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity","volume":"13","author":"Xu","year":"2002","journal-title":"Ann. Oncol."},{"issue":"20","key":"10.1016\/j.lfs.2022.121105_bb0220","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1002\/cmdc.201700454","article-title":"Solubility-improved 10-O-substituted SN-38 derivatives with antitumor activity","volume":"12","author":"Doi","year":"2017","journal-title":"ChemMedChem"},{"issue":"2","key":"10.1016\/j.lfs.2022.121105_bb0225","first-page":"87","article-title":"Review of the role of CPT-11 in the treatment of colorectal cancer","volume":"1","author":"Rougier","year":"2001","journal-title":"Clin. Colorectal Cancer"},{"issue":"6","key":"10.1016\/j.lfs.2022.121105_bb0230","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/cmdc.202000753","article-title":"Synthesis and biological evaluation of 10-substituted camptothecin derivatives with improved water solubility and activity","volume":"16","author":"Yang","year":"2021","journal-title":"ChemMedChem"}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320522008050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320522008050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T21:06:53Z","timestamp":1758402413000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320522008050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":46,"alternative-id":["S0024320522008050"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2022.121105","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-tumor effects and mechanism of a novel camptothecin derivative YCJ100","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2022.121105","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"121105"}}